N. Khan

Long‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ‐I and TOPAZ‐II trials

R. Marinho, D. Dieterich, Armando Carvalho, 2020, Journal of viral hepatitis.